Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor – guidance (TA670)
NICE recommend brigatinib as an option for ALK+ve advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor in adults. It is recommended only if the company provides brigatinib according to the commercial arrangement.
Source:
National Institute for Health and Care Excellence